# Filtricine Preclinical Results Published

**Date:** December 22, 2021  
Filtricine is pleased to announce that the preclinical research results of its proprietary medical food technology.  
[Read more](https://www.filtricine.com/news/filtricine-preclinical-results-published)

---

# Clinical Results Presented at PCF Retreat

**Date:** November 6, 2021  
Filtricine is pleased to announce that researchers leading a Filtricine-sponsored prostate cancer clinical study at Stanford University.  
[Read more](https://www.filtricine.com/news/clinical-results-presented-at-pcf-retreat)

---

# We Are Excited to Announce Filtricine's Latest Round of Investment

**Date:** August 3, 2021  
Filtricine's Seed Round announcement, led by Boutique Venture Partners and Berkeley Catalyst Fund.  
[Read more](https://www.filtricine.com/news/we-are-excited-to-announce-filtricines-latest-round-of-investment-led-by-boutique-venture-partners-and-berkeley-catalyst-fund)

---

# Filtricine Appoints a New Chief Executive Officer

**Date:** December 22, 2020  
It is our great pleasure to announce that Dr. John Chant has accepted our offer as Chief Executive Officer.  
[Read more](https://www.filtricine.com/news/filtricine-appoints-a-new-chief-executive-officer)

---

# Filtricine Initiates the First Clinical Study

**Date:** July 8, 2020  
Filtricine today announced the start of its first human clinical study among prostate cancer patients.  
[Read more](https://www.filtricine.com/news/filtricine-initiates-the-first-clinical-study)

---

# Filtricine Presents Research at Scientific Conference for Cancer Treatment

**Date:** November 1, 2019  
At the AACR-NCI-EORTC conference for molecular targets (#Targets19) in Boston.  
[Read more](https://www.filtricine.com/news/filtricine-research-on-scientific-conference-for-cancer-treatment)

---

# IndieBio Demo Day Presentation

**Date:** November 6, 2018  
We proudly graduated from the phenomenal four-month program at IndieBio.  
[Read more](https://www.filtricine.com/news/indiebio-demo-day-7)

---

We are a clinical-stage biotechnology company based in the San Francisco Bay Area dedicated to developing novel food products for disease control.